Sulfisoxazole - PharmaKB

Sulfisoxazole

Eryzole, Gantrisin, Ilosone Sulfa, Pediazole, Sosol, Soxazole, Sulfalar, Sulsoxin (sulfisoxazole) is a small molecule pharmaceutical. Sulfisoxazole was first approved as Pediazole on 1982-01-01. It is used to treat bacterial infections, chlamydia infections, mycoses, nocardia infections, and otitis media amongst others in the USA.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
infections	D007239
respiratory tract diseases	D012140
otorhinolaryngologic diseases	D010038
urogenital diseases	D000091642
signs and symptoms pathological conditions	D013568

Trade Name

FDA

EMA

No data

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Phenazopyridine hydrochloride

Sulfisoxazole

Tradename	Company	Number	Date	Products
AZO GANTRISIN	Roche	N-019358 DISCN	1990-08-31	1 products, RLD

Hide discontinued

Sulfisoxazole

Tradename	Company	Number	Date	Products
GANTRISIN	Roche	N-006525 DISCN	1982-01-01	1 products

Hide discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
erythromycin ethylsuccinate and sulfisoxazole acetyl	ANDA	2011-01-17

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
mycoses	—	D009181	B35-B49
pain	EFO_0003843	D010146	R52
urinary tract infections	EFO_0003103	D014552	N39.0
otitis media	EFO_0004992	D010033	H66.9
bacterial infections	—	D001424	A49
chlamydia infections	EFO_0007205	D002690	A74.9
protozoan infections	—	D011528	B50-B64
urological manifestations	—	D020924	—
respiratory tract fistula	—	D016156	—
nocardia infections	EFO_0007397	D009617	A43

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

J: Antiinfectives for systemic use

— J01: Antibacterials for systemic use

— J01E: Sulfonamides and trimethoprim antibacterials for systemic use

— J01EB: Short-acting sulfonamides

— J01EB05: Sulfafurazole

S: Sensory organ drugs

— S01: Ophthalmologicals

— S01A: Antiinfective ophthalmologics

— S01AB: Sulfonamides, ophthalmologic antiinfectives

— S01AB02: Sulfafurazole

HCPCS

No data

Clinical

Clinical Trials

2 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Pneumocystis pneumonia	D011020	EFO_0007448	B59	—	—	—	1	—	1

Indications Phases 3

No data

Indications Phases 2

No data

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Osteomyelitis	D010019	EFO_0003102	M86	1	—	—	—	—	1

Indications Without Phase

No data

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Sulfisoxazole
INN	sulfafurazole
Description	Sulfisoxazole is a sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms. It has a role as an antibacterial drug and a drug allergen. It is a member of isoxazoles, a sulfonamide and a sulfonamide antibiotic. It is functionally related to a sulfanilamide.
Classification	Small molecule
Drug class	—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C

Identifiers

PDB	—
CAS-ID	127-69-5
RxCUI	—
ChEMBL ID	CHEMBL453
ChEBI ID	102484
PubChem CID	5344
DrugBank	DB00263
UNII ID	740T4C525W (ChemIDplus, GSRS)

Target

No data

Variants

No data

Financial

Revenue by drug

€

₣

No data

Estimated US medical usage

Sulfisoxazole

Erythromycin

Total medical expenditures per year (USD, in millions)

Mock data
Subscribe for the real data

Number of persons purchased

Mock data
Subscribe for the real data

Number of purchases

Mock data
Subscribe for the real data

Refill frequency

Mock data
Subscribe for the real data

Price per prescription (USD)

Mock data
Subscribe for the real data

Sulfisoxazole

Phenazopyridine

Total medical expenditures per year (USD, in millions)

Mock data
Subscribe for the real data

Number of persons purchased

Mock data
Subscribe for the real data

Number of purchases

Mock data
Subscribe for the real data

Refill frequency

Mock data
Subscribe for the real data

Price per prescription (USD)

Mock data
Subscribe for the real data

Sulfisoxazole

Total medical expenditures per year (USD, in millions)

Mock data
Subscribe for the real data

Number of persons purchased

Mock data
Subscribe for the real data

Number of purchases

Mock data
Subscribe for the real data

Refill frequency

Mock data
Subscribe for the real data

Price per prescription (USD)

Mock data
Subscribe for the real data

Tabular view

Trends

PubMed Central

Top Terms for Disease or Syndrome:

Mock data
Subscribe for the real data

Additional graphs summarizing 2,993 documents

View more details

Safety

Black-box Warning

No Black-box warning

Adverse Events

Top Adverse Reactions

Mock data
Subscribe for the real data

58 adverse events reported

View more details